Hypofractionated accelerated radiotherapy (HART) with concurrent and adjuvant temozolomide in newly diagnosed glioblastoma: a phase II randomized trial (HART-GBM trial).

Supriya MallickHaresh KunhiparambathSubhash GuptaRony BensonSeema SharmaM A LavirajAshish Datt UpadhyayPramod Kumar JulkaDayanand SharmaGoura Kishor Rath

Published in: Journal of neuro-oncology (2018)

HART is comparable to CRT in terms of survival outcome. HART arm had no excess treatment interruption and minimal toxicity. Dose escalation, reduction in overall treatment time, is the advantages with use of HART.

Keyphrases

phase ii
newly diagnosed
clinical trial
open label
early stage
radiation therapy
phase iii
locally advanced
oxidative stress
randomized controlled trial
small cell lung cancer
squamous cell carcinoma
combination therapy
atrial fibrillation
radiation induced